Dashboard
Manage Tickers

SCPHscPharmaceuticals Inc.

Nasdaq scpharmaceuticals.com


$ 5.09 $ 0.05 (0.99 %)    

Friday, 30-Aug-2024 15:59:30 EDT
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 476.00 $ 0.63 (0.13 %)
DIA $ 416.44 $ 1.60 (0.38 %)
SPY $ 563.62 $ 2.85 (0.51 %)
TLT $ 96.60 $ -1.07 (-1.1 %)
GLD $ 231.30 $ -1.09 (-0.47 %)
$ 5.04
$ 5.09
$ 5.09 x 500
$ 5.10 x 293
$ 4.93 - $ 5.09
$ 3.24 - $ 7.82
94,329
na
252.15M
$ 1.09
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-14-2024 06-30-2024 10-Q
2 05-14-2024 03-31-2024 10-Q
3 03-13-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-10-2023 06-30-2023 10-Q
6 05-10-2023 03-31-2023 10-Q
7 03-22-2023 12-31-2022 10-K
8 11-09-2022 09-30-2022 10-Q
9 08-09-2022 06-30-2022 10-Q
10 05-16-2022 03-31-2022 10-Q
11 03-22-2022 12-31-2021 10-K
12 11-09-2021 09-30-2021 10-Q
13 08-11-2021 06-30-2021 10-Q
14 05-12-2021 03-31-2021 10-Q
15 03-23-2021 12-31-2020 10-K
16 11-16-2020 09-30-2020 10-Q
17 08-13-2020 06-30-2020 10-Q
18 05-12-2020 03-31-2020 10-Q
19 03-24-2020 12-31-2019 10-K
20 11-12-2019 09-30-2019 10-Q
21 08-07-2019 06-30-2019 10-Q
22 05-08-2019 03-31-2019 10-Q
23 03-21-2019 12-31-2018 10-K
24 11-13-2018 09-30-2018 10-Q
25 08-14-2018 06-30-2018 10-Q
26 05-07-2018 03-31-2018 10-Q
27 03-21-2018 12-31-2017 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on scPh...
08/19/2024 10:51:56

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

scpharmaceuticals-q2-eps-036-up-from-044-yoy-revenue-81m-up-from-16m-yoy
scPharmaceuticals Q2 EPS $(0.36) Up From $...
08/14/2024 20:02:42

scpharmaceuticals-prices-50m-public-offering-of-12m-shares-of-common-stock-at-a-price-of-4share
scPharmaceuticals Prices $50M Public Offer...
08/12/2024 13:53:57

scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the...

heart-failure-focused-scpharmaceuticals-secures-fda-approval-for-expanded-use-of-furoscix-receives-funding-to-expand-commercialization
Heart Failure-Focused scPharmaceuticals Se...
08/12/2024 13:02:44

FDA approves scPharmaceuticals' expanded Furoscix indication to include NYHA Class IV heart failure patients. scPharmaceuti...

scpharmaceuticals-announces-proposed-underwritten-public-offering-of-common-stock-and-pre-funded-warrants-details-not-disclosed
scPharmaceuticals Announces Proposed Under...
08/12/2024 10:10:22

scpharmaceuticals-announced-non-dilutive-financings-totaling-up-to-125m-from-perceptive-advisors
scPharmaceuticals Announced Non-dilutive F...
08/12/2024 10:08:52

scPharmaceuticals received $75 million through a combination of debt and royalty financings at close, with access to an additio...

the-fda-approves-scpharmaceuticals-supplemental-new-drug-application-seeking-to-expand-the-furoscix-indication-for-heart-failure-patients-at-approval-furoscix-was-only-indicated-for-the-treatment-of-congestion-due-to-fluid-overload-in-adult-patients-with-new-york-heart-association-class-ii-and-class-iii-chronic-heart-failure
The FDA Approves scPharmaceuticals' Supple...
08/12/2024 10:06:57

FUROSCIX is now indicated for the treatment of congestion due to fluid overload in adult patients with chronic heart failure, r...

scpharmaceuticals-announced-topline-results-from-the-pharmacokinetic-study-of-scp-111-an-investigational-low-volume-ph-neutral-formulation-of-furosemide-administered-via-an-autoinjector-as-an-alternative-to-the-current-on-body-infusor-used-with-furoscix
scPharmaceuticals Announced Topline Result...
08/12/2024 10:04:55

Key highlights of the topline results from the study:SCP-111 demonstrated a bioavailability of 107.3% (90% CI: 103.9 - 110.8), ...

scpharmaceuticals-announces-filing-acceptance-of-snda-from-the-fda-seeking-to-expand-furoscix-indication-to-include-chronic-kidney-disease
scPharmaceuticals Announces Filing Accepta...
07/25/2024 12:16:03

scPharmaceuticals Inc. (NASDAQ:SCPH) (the "Company"), a pharmaceutical company focused on developing and commercializin...

hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on scPh...
05/15/2024 10:57:31

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

scpharmaceuticals-q1-2024-gaap-eps-036-beats-044-estimate-sales-610m-beat-598m-estimate
scPharmaceuticals Q1 2024 GAAP EPS $(0.36)...
05/14/2024 20:06:33

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0...

scpharmaceuticals-enrolls-first-participant-in-pivotal-pharmacokinetic-study-of-furoscix-auto-injector-injection
scPharmaceuticals Enrolls First Participan...
04/24/2024 12:01:18

FUROSCIX Auto-injector being developed as a complement to the FUROSCIX On-body Infusor Company anticipates topline data in Q3 2...

12-health-care-stocks-moving-in-fridays-pre-market-session
12 Health Care Stocks Moving In Friday's P...
04/05/2024 12:09:50

hc-wainwright--co-reiterates-buy-on-scpharmaceuticals-maintains-18-price-target
HC Wainwright & Co. Reiterates Buy on scPh...
03/14/2024 11:23:22

HC Wainwright & Co. analyst Douglas Tsao reiterates scPharmaceuticals (NASDAQ:SCPH) with a Buy and maintains $18 price t...

recap-scpharmaceuticals-q4-earnings
Recap: scPharmaceuticals Q4 Earnings
03/13/2024 20:10:19

scpharmaceuticals-q4-2023-gaap-eps-035-beats-042-estimate-sales-6096m-beat-5525m-estimate
scPharmaceuticals Q4 2023 GAAP EPS $(0.35)...
03/13/2024 20:07:12

scPharmaceuticals (NASDAQ:SCPH) reported quarterly losses of $(0.35) per share which beat the analyst consensus estimate of $(0...

earnings-scheduled-for-march-13-2024
Earnings Scheduled For March 13, 2024
03/13/2024 10:15:56

Companies Reporting Before The Bell • Sangamo Therapeutics (NASDAQ:SGMO) is likely to report quarterly loss at $0.26 per share...

a-preview-of-scpharmaceuticalss-earnings
A Preview Of scPharmaceuticals's Earnings
03/12/2024 15:01:58

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
01/22/2024 13:05:58

scpharmaceuticals-sees-prelim-fy23-furoscix-revenue-134m-136m-vs-1282m-est
ScPharmaceuticals Sees Prelim. FY23 FUROSC...
01/04/2024 21:09:29

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION